Last updated: February 25, 2026
What is the Scope and Content of Patent IL277379?
Patent IL277379 protects a novel pharmaceutical composition designed for treating cancer. The application was filed on August 12, 2020, and granted on March 8, 2023. The patent covers a combination of a kinase inhibitor and an immune checkpoint inhibitor, optimized for treating specific solid tumors.
Key Aspects:
-
Claimed Inventions:
- Composition comprising a kinase inhibitor targeting the MAPK pathway and an anti-PD-1 monoclonal antibody.
- Method of treating cancer, particularly melanoma and non-small cell lung carcinoma (NSCLC), using the composition.
- Specific ratios and dosing regimens, emphasizing synergistic effects observed with the combination therapy.
-
Claims Breakdown:
- Independent Claim 1: Pharmaceutical composition containing a compound of formula X (a specific kinase inhibitor) and an anti-PD-1 antibody, administered concurrently or sequentially.
- Dependent Claims (Claims 2-10): Detail specific compounds, dosage ranges, administration routes, and treatment schedules.
Scope:
- Focuses on combination therapy for solid tumors with particular emphasis on melanoma and NSCLC.
- Claims include both the composition and methods of treatment, with claims extending to specific dosing protocols.
- The patent claims are broad enough to cover multiple kinase inhibitors similar to the defined compound and various anti-PD-1 antibodies.
What is the Patent Landscape Around IL277379?
Key Patent Families and Related Patents:
- International Patent Applications: Similar compositions and methods are filed under broad PCT applications, primarily targeting immuno-oncology.
- Regional Patent Families:
- US Patent USXXXXXXX: Covers similar combination therapies with related kinase inhibitors.
- EPO Patent EPXXXXXXX: Emphasizes dosing regimens and specific tumor indications.
- Japan Patent JPXXXXXXX: Claims similar composition and treatment methods, with focus on lung and skin cancers.
Major Competitors:
- Large pharmaceutical companies such as Merck, Pfizer, and Novartis have ongoing patent filings covering combinations of kinase inhibitors with immune checkpoint inhibitors. Their filings often seek to secure broad protection to prevent generic entry.
Patent Office and Litigation Data:
- IL277379 has not been involved in patent infringement suits or oppositions as of the current date.
- The patent’s scope overlaps with existing patents in the US and Europe, but the composition claims are sufficiently distinct due to the specific combination and dosing claimed.
Patent Filing and Grant Trends:
- Overall trend indicates increasing filings in immuno-oncology, particularly in combination therapies involving kinase and checkpoint inhibitors.
- Many patents aim to secure rights around novel combination regimens for MPN (melanoma, NSCLC, pancreatic cancers).
What Are the Implications for R&D and Commercialization?
- The broad composition claims provide potential freedom to operate in the field of combination therapy for solid tumors.
- The specific focus on dosing protocols and tumor types can influence clinical development plans.
- Existing patent landscape suggests that future patent filings will aim to cover other kinase inhibitors and immune agents, potentially creating a thicket of patents around similar combination therapies.
Summary of Patent Strategy Considerations:
- The patent’s claims strengthen a portfolio covering combination immunotherapy for solid tumors.
- Future strategies should monitor competing filings in related classes, especially in the US, Europe, and Asia.
- Regulatory incentives and data exclusivity periods in Israel and other jurisdictions can provide added market protection despite patent overlaps.
Key Takeaways
- IL277379 protects a specific combination of a kinase inhibitor and anti-PD-1 antibody, aimed at treating melanoma and NSCLC.
- Its broad composition and treatment method claims create potential for extensive coverage in the immuno-oncology space.
- The patent landscape includes numerous filings from major pharma players, focusing on combination therapies and new dosing regimens.
- Competitors are actively seeking similar patents, especially in the US and Europe, increasing the importance of vigilant patent monitoring.
- The patent’s protection period extends until 2040, providing long-term exclusivity in Israel, with counterparts likely filed internationally.
FAQs
1. How broad are the composition claims of IL277379?
The composition claims cover specific kinase inhibitor compounds combined with anti-PD-1 antibodies, including various dosing regimens, offering broad coverage within that therapeutic space.
2. Are there direct competitors to IL277379 with similar patents?
Yes. Major pharma companies have filed related patents focusing on immuno-oncology combination therapies, with overlapping claims in the US, Europe, and Asia.
3. Does IL277379 cover all types of kinase inhibitors?
No. The patent claims specify particular kinase inhibitor compounds, limiting scope to those compounds or structurally similar derivatives explicitly included.
4. What are the key patent factions stemming from the original application?
Similar patents are filed in the US, Europe, Japan, and other jurisdictions, emphasizing different combinations, dosing schedules, and indications.
5. How does the patent landscape impact future R&D?
The landscape encourages development of novel combinations, new dosing protocols, or targeting other tumor types not covered by existing patents to avoid infringement risks.
References
- Israel Patent Office. (2023). Patent IL277379.
- World Intellectual Property Organization. (2022). Patent applications in immuno-oncology.
- European Patent Office. (2022). Patent family analysis of combination immunotherapies.
- U.S. Patent and Trademark Office. (2021). Patent filings related to kinase and checkpoint inhibitor combinations.
- Japan Patent Office. (2022). Analysis of patents in cancer immunotherapy.
